News
Form 8.3 - The Vanguard Group, Inc.: Jounce Therapeutics Inc
EQS-News: Eckert & Ziegler Submits Drug Master File for Lu-177 n.c.a.
Puma Biotechnology Reports Fourth Quarter and Full Year Financial Results
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the fourth quarter and year ended December 31, 2022. Unless otherwise stated, all comparisons
QuidelOrtho to Participate in the Raymond James 44th Annual Institutional Investor Conference
QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and
Acadia Healthcare to Participate in March Investor Conferences
Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that the Company will participate in two investor conferences in March.
On Tuesday, March 7, 2023, the Company will participate in
Humana and Aledade Announce 10 Year Collaboration
Aledade, the nation’s largest network of independent primary care, and Humana Inc. (NYSE: HUM), leading health insurer and health care services company, have announced a 10-year collaboration to
Vistagen to Present at Cowen 43rd Annual Health Care Conference
Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system
Silence Therapeutics to Report Fourth Quarter and Full Year 2022 Results on March 15, 2023
Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
EQS-News: Sernova to Participate in Upcoming Roth and Oppenheimer Investor Conferences
Katya Kruglova to join Sonova’s Management Board as GVP Human Resources & Communications
Chemed Corporation to Present at the Oppenheimer 33rd Annual Healthcare Conference
Chemed Corporation (NYSE:CHE) today announced that it will deliver a virtual presentation at the Oppenheimer 33rd Annual Healthcare Conference on Tuesday, March 14, 2023, at approximately 1:20 p.m
QIAGEN and SOPHiA GENETICS Forge Partnership to Combine Strengths in Next-Generation Sequencing
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of the new QIAseq Platform Partnership program and the first partnership with medical data-analysis provider
QIAGEN und SOPHiA GENETICS gehen Partnerschaft ein und bündeln Next-Generation-Sequencing-Kompetenzen
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) startet das „QIAseq Platform Partnership“-Programm und gibt die erste Partnerschaft mit SOPHiA GENETICS™ (Nasdaq: SOPH) bekannt, einem
Vistagen Announces Issuance of U.S. Patent for PH80 Nasal Spray for Treatment of Migraine
Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous
Novocure Announces Last Patient Enrolled in Pivotal METIS Study of Tumor Treating Fields in Brain Metastases from Non-Small Cell Lung Cancer
Novocure (NASDAQ: NVCR) today announced that the final patient has enrolled in the pivotal METIS study evaluating the efficacy of Tumor Treating Fields (TTFields) therapy following stereotactic
Novocure Announces Reimbursement of Optune® for the Treatment of Newly Diagnosed Glioblastoma in France
Novocure (NASDAQ:NVCR) today announced the reimbursement and availability of Optune together with temozolomide (TMZ) for the treatment of adult patients with newly diagnosed glioblastoma (GBM) in
Poxel Announces Publication in Kidney International of PXL770 Preclinical Results in Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Regulatory News:
POXEL SA (Paris:POXEL) (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for serious chronic diseases with metabolic
Pfizer Receives Positive FDA Advisory Committee Votes Supporting Potential Approval for Vaccine Candidate to Help Combat RSV in Older Adults
Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted that available data is adequate
Puma Biotechnology to Participate in a Panel Discussion at Cowen’s 43rd Annual Health Care Conference
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will attend Cowen’s 43rd
Agilent Reports First-Quarter Fiscal Year 2023 Financial Results
Agilent Technologies Inc. (NYSE: A) today reported revenue of $1.76 billion for the first quarter ended January 31, 2023, an increase of 5% compared to the first quarter of 2022 and up 10% on a
Savara Announces New Employment Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to a new employee.
On February 24
Simulations Plus to Present at Raymond James 44th Annual Institutional Investors Conference
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that management will be presenting
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc